High-flying Fujifilm splashes $200M to beef up cell therapy capacity
Fujifilm Corporation is spreading the wealth across two production units as the contract development and manufacturing organization (CDMO) juggernaut works through a cell therapy expansion.The parent company is splitting $200 million between a pair of subsidiaries: Fujifilm Cellular Dynamics, which specializes in development and manufacturing of human induced pluripotent stem cells (iPSC), and the organization’s CDMO for biologics and advanced therapies, Fujifilm Diosynth Biotechnologies.At Fujifilm Cellular Dynamics, a portion of the earmarked sum will go toward a new 175,000-square-foot headquarters in Madison, Wisconsin, Fujifilm Corporation said in a press release Monday.
CYP Price at posting:
11.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)